ArticleFuture oncology (London, England)2025
Association of exosomal miR17-92a cluster and target genes with breast cancer risk.
Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe present study aimed to explore the roles of exosomal microRNAs (miR-17, miR-19b, and miR-92a) and two target genes (PTEN and TGFβR2) in breast cancer risk.
methodsExpression analysis was performed using real-time PCR in a study cohort of 500 patients and 500 age- and sex-matched healthy controls.
resultsThe selected miRNAs (miR-17, p < 0.01; miR-19b, p < 0.01; miR-92a, p < 0.01) and TGFβR2 (p < 0.01) revealed an upregulated expression pattern, whereas downregulation of PTEN (p < 0.05) was observed in cancer patients compared to controls. A significant upregulated expression of miR-17, miR-92a, and TGFβR2 was observed in advanced clinical stages, advanced T-stage, advanced N-stage, and advanced M-stage in breast cancer patients.
conclusionsThese findings demonstrate the oncogenic potential of the selected miRNAs, contributing to breast carcinogenesis. Further analysis showed an association between the expression deregulation of the selected molecules and increased cell proliferation and metastasis. miR-17 and TGFβR2 showed good diagnostic potential with AUCs of 0.708 and 0.909, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.